Hyperlipidemia in chronic kidney disease

International Journal of Artificial Organs

Volumn 30, Issue 11, 2007, Pages 987-992

  Kaysen, George A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apo A l; Apo A ll; Apo C lll; CETP; Chylomicrons; Hepatic lipase; IDL; LCAT; Lp(a)

Indexed keywords

CHOLESTEROL; DIALYSIS; ESTERS; LIPOPROTEINS;

APO A-L; APO A-LL; APO C-LLL; CETP; CHYLOMICRON; DENSITY LIPOPROTEINS; HEPATIC LIPASE; INTERMEDIATE DENSITIES; INTERMEDIATE DENSITY LIPOPROTEIN; LCAT; LP(A);

NUTRITION;

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; KIDNEY CLEARANCE; MOLECULAR WEIGHT; MORTALITY; NONHUMAN; OBESITY; RISK FACTOR;

EID: 38149070113     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703001107     Document Type: Article

References (46)

1. U.S. Renal Data System. USRDS 2005 Annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005; 128-9.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
3. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-93.
4. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 2603-11.
5. Okubo K, Ikewaki K, Sakai S, et al. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004; 15: 1008-15.
6. Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41: 203-11.
7. Shoji T, Nishizawa Y, Kawagishi T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atheroscleresis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277-84.
8. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-76.
9. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-14.
10. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
11. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290: 262-72.
12. Deighan CJ, Caslake MJ, McConnell M, et. al. Related Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000; 35: 852-62.
13. Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2615-22.
14. Wakabayashi Y, Okubo M, Shimada H, Sato N, Koide A, Marumo F, Nakamura H. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. Metabolism 1987; 36: 815-20.
15. Alsayed N, Rebourcet R. Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients. Clin Chem 1991; 37: 387-93.
16. Hirano T, Sakaue T, Misaki A, et al. Very low-density lipoprotein-apoprotein C I is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 2003; 63: 2171-7.
17. Mekki K, Bouchenak M, Remaoun M, Belleville JL. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study. Med Sci Monit 2004; 10: CR439-46.
18. Espino-Montoro A, Barrios-Artillo M, Lopez-Chozas JM, et al. Influence of polymorphism (RFLP-sstl) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism. Nutr Metab Cardiovasc Dis 2003; 13: 194-201.
19. Malmendier CL, Lontie JF, Delcroix C, et al. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989; 77: 139-49.
20. Miida T, Miyazaki O, Hanyu O, et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003; 14: 732-8.
21. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5: 379-87.
22. Welty FK, Lichtenstein AH, Barrett PH, et al. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 2004; 24: 1703-7.
23. Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2615-22.
24. Kobayashi S, Maesato K, Moriya H, et al. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-80.
25. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-8.
26. Anderwald C, Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev 2004; 1: 310-9.
27. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-25.
28. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15: 538-48.
29. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN. Related LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 2002; 35: 211-6.
30. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-62.
31. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in Renal Disease Study. Kidney Int 1997; 51: 1908-19.
32. Elshourbagy, N A, Boguski M S, Liao WS, et al. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci U S A 1985; 82:8242-6.
33. Quintao EC, Medina WL, Passarelli M. Related Reverse cholesterol transport in diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 237-50.
34. Sparks DL, Davidson WS, Lund-Katz S, Phillips MC. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 1995; 270: 26910-7.
35. Moestrup SK, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000; 11: 133-40.
36. Ooi EM, Watts GF, Farvid MS, et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 2005; 13: 1008-16.
37. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47: 1928-34.
38. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-38.
39. Mendez AJ, Perez GO, Hsia SL. Defect in cholesteryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: increased inhibitor activity for cholesteryl ester transfer. J Lab Clin Med 1988; 111: 677-83.
40. Chan MK, Ramdial L, Varghese Z, et al. Plasma LCAT activities in renal allograft recipients. Clin Chim Acta 1982; 124: 187-93.
41. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 2153-61.
42. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-15.
43. De Sain-Van Der Velden MG, Reijngoud DJ, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9: 1474-81.
44. Kuboyama M, Ageta M, Ishihara T, et al. Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb 2003; 10: 283-9.
45. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16: 1794-802.
46. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kilic M. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-5.